surmount-1 tirzepatide trial weight loss non-diabetic obesity In the (published in NEJM in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor surmount-1 Tirzepatide for maintenance of bodyweight
Pay in 4 interest-free payments of $6.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
00656-2/asset/09a3e122-d7af-44ed-abbd-db334fe4ca36/main.assets/gr3.jpg)


























